Demant 과거 수익 실적

과거 기준 확인 2/6

Demant은 연평균 15.5%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 증가했으며, 연간 1.9%였습니다. 매출은 연평균 10.9%의 비율로 증가했습니다. Demant의 자기자본이익률은 26.7%이고 순이익률은 11.1%입니다.

주요 정보

15.5%

수익 성장률

17.6%

EPS 성장률

Medical Equipment 산업 성장	-9.5%
매출 성장률	10.9%
자기자본 수익률	26.7%
순이익	11.1%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Demant 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BATS-CHIXE:DEMANC 수익, 비용 및 수입 (DKK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	22,836	2,535	11,490	1,536
31 Mar 24	22,640	2,544	11,263	1,473
31 Dec 23	22,443	2,552	11,036	1,410
30 Sep 23	21,442	2,577	10,732	1,291
30 Jun 23	20,902	2,488	10,633	1,270
31 Mar 23	20,304	2,381	10,440	1,292
31 Dec 22	19,705	2,274	10,246	1,314
30 Sep 22	19,181	2,460	9,851	1,274
30 Jun 22	18,656	2,645	9,455	1,233
31 Mar 22	18,281	2,671	9,178	1,186
31 Dec 21	17,905	2,696	8,900	1,139
30 Sep 21	17,521	2,453	8,651	1,170
30 Jun 21	17,137	2,209	8,401	1,200
31 Mar 21	15,803	1,665	8,145	1,231
31 Dec 20	14,469	1,121	7,889	1,261
30 Sep 20	14,072	970	7,952	1,224
30 Jun 20	13,674	818	8,014	1,186
31 Mar 20	14,310	1,140	8,138	1,153
31 Dec 19	14,946	1,462	8,261	1,120
30 Sep 19	14,728	1,579	8,068	1,093
30 Jun 19	14,510	1,695	7,874	1,066
31 Mar 19	14,224	1,759	7,593	1,030
31 Dec 18	13,937	1,823	7,312	994
30 Sep 18	13,699	1,836	7,084	956
30 Jun 18	13,461	1,849	6,856	918
31 Mar 18	13,325	1,802	6,809	887
31 Dec 17	13,189	1,754	6,762	856
30 Sep 17	12,943	1,689	6,680	831
30 Jun 17	12,697	1,624	6,597	806
31 Mar 17	12,350	1,542	6,436	795
31 Dec 16	12,002	1,459	6,275	784
30 Sep 16	11,717	1,429	6,068	787
30 Jun 16	11,432	1,399	5,860	790
31 Mar 16	11,049	1,418	5,573	777
31 Dec 15	10,665	1,436	5,285	763
30 Sep 15	10,258	1,402	5,090	731
30 Jun 15	9,850	1,367	4,894	699
31 Mar 15	9,598	1,347	4,693	690
31 Dec 14	9,346	1,326	4,491	680
30 Sep 14	9,221	1,301	4,420	673
30 Jun 14	9,095	1,275	4,348	665
31 Mar 14	9,027	1,280	4,294	650
31 Dec 13	8,959	1,285	4,239	634

양질의 수익: DEMANC 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: DEMANC 의 현재 순이익 이익률 (11.1%) 작년보다 낮습니다 (11.9%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: DEMANC 의 수입은 지난 5년 동안 매년 15.5% 씩 증가했습니다.

성장 가속화: 지난 1년간 DEMANC 의 수익 증가율( 1.9% )은 5년 평균( 15.5% 보다 낮습니다. 년도).

수익 대 산업: 지난 1년간 DEMANC 수익 성장( 1.9% )은 Medical Equipment 업계 39.9% 능가하지 못했습니다. 39.9%.

자기자본 수익률

높은 ROE: DEMANC 의 자본 수익률( 26.65% )이 높음이지만, 이 지표는 높은 부채 수준으로 인해 왜곡됩니다.

Demant 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기